Daily as of 3 Nov 16:00 ET
- Price
- above both $99.27 vs 50 $89.69 / 200 $73.87
- Projection
- No cross projected
- Test
- No active test
- Last cross
- 🟨Golden cross 22 Oct 2025 · projected 30 bars out
SYRE | Spyre TherapeuticsNASDAQHealthcareCommon stock golden cross and death cross projections, cross tests and history
$99.27
+$3.76 (+3.94%)
Spyre Therapeutics (SYRE) is a NASDAQ-listed common stock that Cruxta has tracked for 50/200 crosses since 2024.
The 50 SMA has sat above the 200 on the daily since Oct 2025, with no cross projected inside the 30 bars Cruxta tracks. Price sits above the 50 and the 200 on the daily and the 4-hour.
Timeframe summary
Weekly
No weekly data
4-hour as of 3 Nov 13:30 ET
- Price
- above both $99.33 vs 50 $88.94 / 200 $93.38
- Projection
- 🟨Golden cross estimated in 14 to 19 bars
- Test
- No active test
- Last cross
- 💀Death cross 30 Sep 2026 bar 1 · projected 11 bars out · tested 3 bars
Cross history
| Crossed | Direction | Timeframe | Projected | Cross test |
|---|---|---|---|---|
| 30 Sep 2026 | 💀Death | 4-hour | 11 bars out | 3 bar cross test |
| 22 Oct 2025 | 🟨Golden moderate | daily | 30 bars out | Not tested |
| 21 Nov 2024 | 💀Death | daily | 7 bars out | Not tested |
| 13 Nov 2024 | 🟨Golden | daily | 23 bars out | 2 bar cross test |
About SYRE
ExchangeNASDAQ
InstrumentCommon stock
Median $ volume, 60 d$97.4M
4-hour coverageYes, since Oct 2025
History on recordSince 2024
SectorHealthcare
Cap bandmid